Overview

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy of oral fluvoxamine in olfactory improvement following Covid-19- associated parosmia. This is a randomized, double-blinded, placebo-controlled trial.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Fluvoxamine